Fig 5 - by Dennis Ochola (11626912)

Performance of selected antimalarials against field isolates during the study period. by Winnie Okore (14139712)

Subjects:

Primers used for analysis of four SNPs in one gene. by Winnie Okore (14139712)

Subjects:

Number of samples per site during the study period. by Winnie Okore (14139712)

Subjects:

Performance of selected drugs against field isolates during the study period. by Winnie Okore (14139712)

Subjects:

<i>In vitro</i> susceptibility responses of field isolates to antimalarials during the study period. by Winnie Okore (14139712)

Subjects:

<i>Pfmrp1</i> gene SNPs data during the study period. by Winnie Okore (14139712)

Subjects:

Frequency of SNPs in <i>Pfmrp1</i> gene in field isolates during the study period. by Winnie Okore (14139712)

Subjects:

<i>In vitro</i> 95% CI lower and upper mean susceptibility responses of field isolates to antimalarials. by Winnie Okore (14139712)

Subjects:

Effects of SNPs on the Protein Stability, Increasing or Decreasing. by Mirza Jawad Ul Hasnain (8351388)

Comparison of wind roses between ERA5 reanalysis and in-situ measured data. a: W03 station, b: W08 station, c: W13 station and d: W19 station. by Weidong Ji (129916)

SARS-CoV-2 induced lung inflammation is increased with IL-10 blockade and decreased with IFNγ blockade. by Christine E. Nelson (18946410)

Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W1... by Weidong Ji (129916)

Ppk1 levels are not affected by decreasing dendrite arbor size but are reduced when dendrite length increases. by Josephine W. Mitchell (17364781)

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric <i>in silico</i> ROCOCO trial by Daniëlle B. P. Eekers (5560430)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Trial profile. by Chanel Avenant (409756)

“…We measured testosterone by UHPLC-MS/MS and SHBG by immunoassay in matched pairs of serum samples collected at baseline (D0) and at peak serum progestin levels at 25 weeks post initiation (25W) (n = 214–218 pairs). Both contraceptives substantially decreased, from D0 to 25W, the total testosterone [DMPA-IM D0 0.560, 25W 0.423 nmol/L, -24.3% (p < 0.0001); NET-EN D0 0.551, 25W 0.253 nmol/L, -54.1%, (p < 0.0001)], SHBG [DMPA-IM D0 45.0, 25W 32.7 nmol/L, -29.8% (p < 0.0001); NET-EN D0 50.2, 25W 17.6 nmol/L, -65.1% (p < 0.0001)], and calculated free testosterone levels [DMPA-IM D0 6.87, 25W 5.38 pmol/L, -17.2% (p = 0.0371); NET-EN D0 6.00, 25W 3.70, -40.0% (p < 0.0001)]. …”

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)